Cost-effectiveness of subcutaneous ketamine in the management of chronic cancer pain

Nicola McCaffrey, Thomas Flint, Billingsley Kaambwa, Belinda Fazekas, David Currow, Janet Hardy, Meera Agar, Simon Eckermann

    Research output: Contribution to conferencePaperpeer-review

    Abstract

    Study implications:
    –No statistically significant difference in responder rates but higher toxicity and worse QOL
    –Higher ketamine costs despite lower costs for other medications
    –When costs and QOL are jointly considered, ketamine is neither effective nor cost-effective
    Original languageEnglish
    Number of pages23
    Publication statusPublished - May 2015
    Event13th Australian Palliative Care Conference Melbourne: Fit for the future - Melbourne Convention and Exhibition Centre, Melbourne, Australia
    Duration: 1 Sep 20154 Sep 2015
    Conference number: 13

    Conference

    Conference13th Australian Palliative Care Conference Melbourne
    CountryAustralia
    CityMelbourne
    Period1/09/154/09/15

    Keywords

    • End-of-life care
    • palliative medicine
    • ketamine
    • pain management

    Fingerprint Dive into the research topics of 'Cost-effectiveness of subcutaneous ketamine in the management of chronic cancer pain'. Together they form a unique fingerprint.

    Cite this